Degrader-antibody conjugates (DACs) typically consist of a tumor-targeting antibody and a conjugated degrader payload, linked via a chemical linker. By integrating the degrader payload’s capacity to precisely degrade disease-causing proteins with the antibody’s tumor-targeting specificity, DACs emerge as an innovative and promising therapeutic modality for cancer treatment. Herein, we present the well-established DAC integrated platform developed by ICE Bioscience, which facilitates the characterization and evaluation of DACs from in vitro assays to in vivo studies.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
